Psychedelic Drugs

A new study indicates that brief experiences with inhaled DMT can reduce anxiety and improve life satisfaction. For patients with treatment-resistant depression, the substance combined with therapy might promote long-lasting enhancements in overall quality of life.

A single dose of psilocybin can alter brain communication for up to a month. New research suggests the psychedelic increases brain flexibility and shifts information flow, offering clues to its lasting effects on mental health.

A new study on marmosets suggests ayahuasca could protect the brain from physical damage caused by chronic stress, pointing to the psychedelic brew's potential as a preventative treatment for depression.

Researchers analyzing nationwide survey data found that adults using psilocybin infrequently alongside alcohol reported less anxiety and depression than non-psilocybin users, suggesting potential benefits outside clinical settings.

A pilot clinical trial suggests that psilocybin combined with psychotherapy is safe and well-tolerated by veterans with severe, treatment-resistant PTSD. The study found that most participants no longer met the diagnostic criteria for PTSD.

New brain scans show that drugs like LSD, psilocybin, and MDMA reliably reduce the upward flow of information into a core brain network. This surprising shift offers a biological explanation for their psychological risks and benefits.

A recent study published in Neuropsychopharmacology reveals that a single dose of LSD can improve motor learning the following day. The psychedelic drug also appears to reduce perceived stress and alter brain activity up to a week later.

New research indicates that psilocybin, the active compound in magic mushrooms, might protect human skin cells from premature aging. In laboratory tests, the psychedelic compound reduced inflammation and cellular stress caused by high sugar and fat levels.

A renewed scientific interest in psychedelics is yielding surprising discoveries about LSD.

Brain imaging reveals that LSD works by quieting local electrical rhythms and severing small-scale synchronization in the cortex. This fragmentation forces the brain to globally integrate sensory data, fundamentally altering human consciousness and perception.

A new computer simulation based on brain scans shows how LSD alters the balance of excitement and inhibition in specific neural circuits. These chemical changes silence sensory pathways and boost abstract thought, unifying the brain into a highly synchronized state.

Could psychedelics help prevent migraines? A new study of identical twins suggests that men who use substances like psilocybin and LSD have nearly three times lower odds of experiencing migraines compared to their twin brothers who don't.

In recent FDA Phase 2 trials, a single dose of the experimental psychedelic luvesilocin eliminated postpartum depression symptoms in 71% of patients within seven days. The breakthrough medication will enter Phase 3 trials by late 2026.

A new review of nearly 50 studies suggests classic psychedelics like psilocybin and LSD can cause lasting personality changes. Research links the use of these substances to long-term increases in openness and significant drops in neuroticism.

A single dose of psilocybin reduces the drive to seek out rewards by increasing the activity of inhibitory brain cells. These findings help explain how psychedelics might induce long-lasting changes in brain circuits to treat substance use disorders.